United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 125 mg - divalproex sodium delayed-release tablets are a valproate and are indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. the efficacy of divalproex sodium delayed-release tablets was established in 3 week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania [see clinical studies (14.1)]. the safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the dr

United States - English - NLM (National Library of Medicine)

ucyclyd pharma inc. - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - ammonul is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see warnings and precautions (5) ]. none. pregnancy category c. animal reproduction studies have not been conducted with ammonul. it is not known whether ammonul can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. thus, ammonul should be given to a pregnant woman only if clearly needed. it is not known whether sodium phenylacetate, sodium benzoate, or their conjugation products are excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when ammonul is administered to a nursing woman. ammonul has been used as a treat

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 550 mg - carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen tablets or naproxen sodium tablets. use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). naproxen as naproxen tablets or naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis for the relief of the signs and symptoms of osteoarthritis for the relief of the signs and symptoms of ankylosing spondylitis for the relief of the signs and symptoms of juvenile arthritis - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen as naproxen tablets or naproxen so

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - divalproex sodium (unii: 644vl95ao6) (valproic acid - unii:614oi1z5wi) - valproic acid 500 mg - divalproex sodium delayed release tablets are a valproate and are indicated for the treatment of the manic episodes associated with bipolar disorder. a manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. the efficacy of divalproex sodium delayed release tablets were established in 3-week trials with patients meeting dsm-iii-r criteria for bipolar disorder who were hospitalized for acute mania [see clinical studies ( 14.1)] . the safety and effectiveness of divalproex sodium delayed release tablets for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. therefore, healthcare providers who elect to use divalproex sodium delayed release tablets for extended periods should continually reevaluate the long-term usefulness of t

United States - English - NLM (National Library of Medicine)

mutual pharmaceutical company, inc. - tolmetin sodium (unii: 02n1tzf99f) (tolmetin - unii:d8k2jpn18b) - tolmetin 400 mg - carefully consider the potential benefits and risks of tolmetin sodium and other treatment options before deciding to use tolmetin sodium. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). tolmetin sodium is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. tolmetin sodium is indicated in the treatment of acute flares and the long-term management of the chronic disease. tolmetin sodium is also indicated for treatment of juvenile rheumatoid arthritis. the safety and effectiveness of tolmetin sodium have not been established in pediatric patients under 2 years of age (see precautions: pediatric use and dosage and administration ). tolmetin sodium is contraindicated in patients with known hypersensitivity to tolmetin sodium. tolmetin sodium should not be given to patients who have experienced asthma, urticaria or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, an

United States - English - NLM (National Library of Medicine)

akorn - sodium nitroprusside (unii: eao03pe1tc) (nitroprusside - unii:169d1260km) - sodium nitroprusside 50 mg in 2 ml - sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (a.s.a. class 5e) coming to emergency surgery. patients with congenital (leber's) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. these rare condition

United States - English - NLM (National Library of Medicine)

hikma pharmaceutical - naproxen sodium (unii: 9tn87s3a3c) (naproxen - unii:57y76r9atq) - naproxen sodium 275 mg - carefully consider the potential benefits and risks of naproxen sodium tablets and other treatment options before deciding to use naproxen sodium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). naproxen sodium tablets are indicated: - for the relief of the signs and symptoms of rheumatoid arthritis - for the relief of the signs and symptoms of osteoarthritis - for the relief of the signs and symptoms of ankylosing spondylitis - for the relief of the signs and symptoms of juvenile arthritis naproxen sodium tablets are also indicated: - for relief of the signs and symptoms of tendonitis - for relief of the signs and symptoms of bursitis - for relief of the signs and symptoms of acute gout - for the management of pain - for the management of primary dysmenorrhea naproxen sodium is contraindicated in patients with known hypersensitivity to naproxen and naproxen sodium. naproxen sodium should not be given to patients who have expe

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of the dosage and administration section.) previously, neona

United States - English - NLM (National Library of Medicine)

sigmapharm laboratories, llc - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate 0.94 g in 1 g - sodium phenylbutyrate powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (see nutritional supplementation subsection of t

United States - English - NLM (National Library of Medicine)

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium acetate anhydrous (unii: nvg71zz7p0) (sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838) - sodium chloride 526 mg in 100 ml - normosol-r ph 7.4 is indicated for replacement of acute extracellular fluid volume losses in surgery, trauma, burns or shock. normosol-r ph 7.4 also can be used as an adjunct to restore a decrease in circulatory volume in patients with moderate blood loss. normosol-r ph 7.4 is not intended to supplant transfusion of whole blood or packed red cells in the presence of uncontrolled hemorrhage or severe reductions of red cell volume. normosol-r ph 7.4 is particularly valuable as a solution for use in starting blood, i.e., as a priming solution for the infusion set. no hemolysis of blood is seen at the interface or with mixed solution and blood. it may also be used as a diluent to aid in the transfusion of packed red blood cells (prbc). normosol-r ph 7.4 and physiologic saline solution (0.9% sodium chloride injection, usp) are compatible with both young and old prbc. none known.